Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$9.77 - $21.47 $5,529 - $12,152
566 New
566 $8,000
Q2 2018

Aug 14, 2018

SELL
$19.78 - $24.67 $771 - $962
-39 Closed
0 $0
Q1 2018

May 02, 2018

BUY
$18.89 - $32.46 $736 - $1,265
39 New
39 $1,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $199M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Hanseatic Management Services Inc Portfolio

Follow Hanseatic Management Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hanseatic Management Services Inc with notifications on news.